Kestra Medical Technologies, Ltd. (KMTS)
NASDAQ: KMTS · Real-Time Price · USD
28.00
+0.10 (0.36%)
Aug 12, 2026, 4:00 PM EDT - Market closed
KMTS Revenue
In the fiscal year ending April 30, 2026, Kestra Medical Technologies had annual revenue of $95.13M with 59.03% growth. Kestra Medical Technologies had revenue of $28.64M in the quarter ending April 30, 2026, with 66.18% growth.
Revenue (ttm)
$95.13M
Revenue Growth
+59.03%
P/S Ratio
17.25
Revenue / Employee
$214,731
Employees
443
Market Cap
1.64B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2026 | 95.13M | 35.31M | 59.03% |
| Apr 30, 2025 | 59.82M | 32.00M | 115.05% |
| Apr 30, 2024 | 27.81M | 20.18M | 264.53% |
| Apr 30, 2023 | 7.63M | - | - |
| Apr 30, 2021 | - | - | - |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DENTSPLY SIRONA | 3.64B |
| ICU Medical | 2.16B |
| Warby Parker | 911.61M |
| Azenta | 613.81M |
| AtriCure | 569.62M |
| STAAR Surgical Company | 339.59M |
| AngioDynamics | 320.17M |
| LeMaitre Vascular | 262.43M |
KMTS News
- 3 days ago - Kestra Medical initiated with an Overweight at JPMorgan - TheFly
- 16 days ago - Kestra Medical Technologies Proxy statement: Proxy filing - Filings
- 16 days ago - Kestra Medical Technologies Proxy statement: Proxy filing - Filings
- 23 days ago - Kestra Medical initiated with a Perform at Oppenheimer - TheFly
- 4 weeks ago - Kestra Medical price target raised to $32 from $30 at BTIG - TheFly
- 4 weeks ago - Kestra Medical Technologies Earnings Call Transcript: Q4 2026 - Transcripts
- 4 weeks ago - Kestra Medical Technologies Earnings release: Q4 2026 - Filings
- 4 weeks ago - Kestra Medical Technologies Annual report: Q4 2026 - Filings